miR-21 regulates triglyceride and cholesterol metabolism in non-alcoholic fatty liver disease by targeting HMGCR

International Journal of Molecular Medicine

Volumn 35, Issue 3, 2015, Pages 847-853

  Sun, Chuanzheng ^a   Huang, Feizhou ^a   Liu, Xunyang ^a   Xiao, Xuefei ^a   Yang, Mingshi ^a   Hu, Gui ^a   Liu, Huaizheng ^a   Liao, Liangkan ^a  

^a THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

HMGCR; miR 21; Non alcoholic fatty liver disease

Indexed keywords

BIOLOGICAL MARKER; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MICRORNA; OLEIC ACID; PALMITIC ACID; PROTEIN; TRIACYLGLYCEROL; 3' UNTRANSLATED REGION; HMGCR PROTEIN, HUMAN; MESSENGER RNA; MIRN21 MICRORNA, HUMAN;

ARTICLE; BLOOD LEVEL; CHOLESTEROL METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME DEGRADATION; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; LUCIFERASE ASSAY; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROTEIN FUNCTION; 3' UNTRANSLATED REGION; CASE CONTROL STUDY; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; RNA INTERFERENCE;

3' UNTRANSLATED REGIONS; CASE-CONTROL STUDIES; CHOLESTEROL; GENE EXPRESSION REGULATION; HEP G2 CELLS; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; MICRORNAS; NON-ALCOHOLIC FATTY LIVER DISEASE; RNA INTERFERENCE; RNA, MESSENGER; TRIGLYCERIDES;

EID: 84921718665     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2015.2076     Document Type: Article

References (29)

1. Targher G, Bertolini L, Padovani R, et al: Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30: 1212-1218, 2007.
2. Clark JM and Diehl AM: Hepatic steatosis and type 2 diabetes mellitus. Curr Diab Rep 2: 210-215, 2002.
3. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G and Bellentani S: Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 42: 44-52, 2005.
4. Browning JD, Szczepaniak LS, Dobbins R, et al: Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40: 1387-1395, 2004.
5. Vernon G, Baranova A and Younossi ZM: Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34: 274-285, 2011.
6. Fan JG: An introduction of strategies for the management of nonalcoholic fatty liver disease (NAFLD) recommended by Asia Pacific Working Party on NAFLD. Zhonghua Gan Zang Bing Za Zhi 15: 552-553, 2007 (In Chinese).
7. Ballestri S, Lonardo A, Bonapace S, Byrne CD, Loria P and Targher G: Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J Gastroenterol 20: 1724-1745, 2014.
8. Oni ET, Agatston AS, Blaha MJ, et al: A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis 230: 258-267, 2013.
9. Nelson KM and Weiss GJ: MicroRNAs and cancer: past, present, and potential future. Mol Cancer Ther 7: 3655-3660, 2008.
10. Xu P, Guo M and Hay BA: MicroRNAs and the regulation of cell death. Trends Genet 20: 617-624, 2004.
11. Karp X and Ambros V: Encountering microRNAs in cell fate signaling. Science 310: 1288-1289, 2005.
12. Li S, Chen X, Zhang H, et al: Differential expression of microRNAs in mouse liver under aberrant energy metabolic status. J Lipid Res 50: 1756-1765, 2009.
13. Cheung O, Puri P, Eicken C, et al: Nonalcoholic steatohepatitis is associated with altered hepatic microRNA expression. Hepatology 48: 1810-1820, 2008.
14. Jin X, Ye YF, Chen SH, Yu CH, Liu J and Li YM: MicroRNA expression pattern in different stages of nonalcoholic fatty liver disease. Dig Liver Dis 41: 289-297, 2009.
15. Pogribny IP, Starlard-Davenport A, Tryndyak VP, Han T, Ross SA, Rusyn I and Beland FA: Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice. Lab Invest 90: 1437-1346, 2010.
16. Cazanave SC, Mott JL, Elmi NA, et al: JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis. J Biol Chem 284: 26591-26602, 2009.
17. Ahn J, Lee H, Jung CH and Ha T: Lycopene inhibits hepatic steatosis via microRNA-21-induced downregulation of fatty acid-binding protein 7 in mice fed a high-fat diet. Mol Nutr Food Res 56: 1665-1674, 2012.
18. Nehra V, Angulo P, Buchman AL and Lindor KD: Nutritional and metabolic considerations in the etiology of nonalcoholic steatohepatitis. Dig Dis Sci 46: 2347-2352, 2001.
19. Richieri GV and Kleinfeld AM: Unbound free fatty acid levels in human serum. J Lipid Res 36: 229-240, 1995.
20. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al: Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120: 1183-1192, 2001.
21. Belfort R, Harrison SA, Brown K, et al: A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355: 2297-2307, 2006.
22. Yao HR, Liu J, Plumeri D, et al: Lipotoxicity in HepG2 cells triggered by free fatty acids. Am J Transl Res 3: 284-291, 2011.
23. Beg ZH, Stonik JA and Brewer HB Jr: Phosphorylation of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase and modulation of its enzymic activity by calcium-activated and phospholipid-dependent protein kinase. J Biol Chem 260: 1682-1687, 1985.
24. Beg ZH, Stonik JA and Brewer HB Jr: Modulation of the enzymic activity of 3-hydroxy-3-methylglutaryl coenzyme A reductase by multiple kinase systems involving reversible phosphorylation: a review. Metabolism 36: 900-917, 1987.
25. Caballero F, Fernández A, De Lacy AM, Fernández-Checa JC, Caballería J and García-Ruiz C: Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. J Hepatol 50: 789-796, 2009.
26. Min HK, Kapoor A, Fuchs M, et al: Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab 15: 665-674, 2012.
27. DeBose-Boyd RA: Feedback regulation of cholesterol synthesis: sterolaccelerated ubiquitination and degradation of HMG CoA reductase. Cell Res 18: 609-621, 2008.
28. Trapani L, Segatto M, Simeoni V, et al: Short- and long-term regulation of 3-hydroxy 3-methylglutaryl coenzyme A reductase by a 4-methylcoumarin. Biochimie 93: 1165-1171, 2011.
29. Maron DJ, Fazio S and Linton MF: Current perspectives on statins. Circulation 101: 207-213, 2000.